Bleeding risks with novel oral anticoagulants especially rivaroxaban versus aspirin: a meta-analysis

Autor:	Xiehui Chen, Weichao Huang, Aimei Sun, Lili Wang, Fanrui Mo, Wenqin Guo
Jazyk:	angličtina
Rok vydání:	2021
Předmět:	Anticoagulants Aspirin Intracranial hemorrhages Gastrointestinal hemorrhage Diseases of the blood and blood-forming organs RC633-647.5
Zdroj:	Thrombosis Journal, Vol 19, Iss 1, Pp 1-11 (2021)
Druh dokumentu:	article
ISSN:	1477-9560
DOI:	10.1186/s12959-021-00322-6
Popis:	Abstract Background This pairwise meta-analysis determines the difference in bleeding risks associated with the use of novel oral anticoagulants (NOACs) and aspirin. Methods PubMed, the Cochrane Library database, clinicaltrial.gov , and related studies were searched for randomized control trials (RCTs) comparing NOAC and aspirin published between January 1, 2000 and May 10, 2021. The primary endpoint was intracranial hemorrhage (ICH). Results Eleven studies involving 57,645 patients were included. Compared to aspirin, rivaroxaban (5 mg/day) had a similar risk of ICH, major bleeding, and fatal bleeding; rivaroxaban (10 mg/day) had higher risks of gastrointestinal hemorrhage (OR: 1.41; 95% CI: 1.03–1.94; P = 0.032; I2 = 0%) and a similar risk of ICH, major bleeding, and fatal bleeding; and rivaroxaban (15–20 mg/day) had higher risks of ICH (OR: 3.21; 95% CI: 1.36–7.60; P = 0.008; I2 = 0%), major bleeding (OR: 2.64; 95% CI: 1.68–4.16; P
Databáze:	Directory of Open Access Journals
Externí odkaz:	https://doaj.org/article/f66d4d3c34ab43bab1d0453e866d05f7 Zobrazit plný text záznamu View record in DOAJ Plný text ve formátu PDF Plný text ve formátu HTML
Nepřihlášeným uživatelům se plný text nezobrazuje	K zobrazení výsledku je třeba se přihlásit.